PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30317758-11	2018	Blocking JNK pathway by SP600125, the expression of DR4 and DR5 decreased (P < 0.05), Bax expression decreased and Bcl2 expression increased compared with HNK+TRAIL group.	pyrazolanthrone	24-32	TNF receptor superfamily member 10a	Homo sapiens	52-55	
23007278-8	2012	Pretreatment with the c-Jun N-terminal kinase (JNK) inhibitor SP600125 and the reactive oxygen species (ROS) scavenger N-acetylcysteine reduced the SVT and TRAIL-induced upregulation of DR4 and DR5 expression, expression of the apoptosis related protein such as caspase-3 and-9, as well as cell growth inhibitory effects.	pyrazolanthrone	62-70	TNF receptor superfamily member 10a	Homo sapiens	186-189	
26822174-6	2016	Antioxidant N-acetyl-L-cysteine (NAC) and c-Jun NH2-terminal kinase (JNK) inhibitor SP600125 inhibited PEITC-induced DR4 and DR5 expression.	pyrazolanthrone	84-92	TNF receptor superfamily member 10a	Homo sapiens	117-120	
23857473-8	2013	In contrast, JNK-specific inhibition, by SP600125, triggered upregulation of DR4 and DR5, and sensitized SK-Hep1 cells to TRAIL, indicating that the CAPE-induced suppression of JNK may contribute to the sensitizing effect of CAPE through the upregulation of death receptors.	pyrazolanthrone	41-49	TNF receptor superfamily member 10a	Homo sapiens	77-80	
18645026-7	2008	Pretreatment with an antioxidant (N-acetylcysteine) or a c-Jun NH(2)-terminal kinase inhibitor (SP600125) effectively prevented Andro-induced p53 activation and DR4 up-regulation and eventually blocked the Andro-induced sensitization on TRAIL-induced apoptosis.	pyrazolanthrone	96-104	TNF receptor superfamily member 10a	Homo sapiens	161-164